200 related articles for article (PubMed ID: 27472081)
21. Small Interfering RNA Targeted to ASPP2 Promotes Progression of Experimental Proliferative Vitreoretinopathy.
Chen XL; Bai YJ; Hu QR; Li SS; Huang LZ; Li XX
Mediators Inflamm; 2016; 2016():7920631. PubMed ID: 27378826
[TBL] [Abstract][Full Text] [Related]
22. Retrovirus-mediated suicide gene transduction in the vitreous cavity of the eye: feasibility in prevention of proliferative vitreoretinopathy.
Kimura H; Sakamoto T; Cardillo JA; Spee C; Hinton DR; Gordon EM; Anderson WF; Ryan SJ
Hum Gene Ther; 1996 May; 7(7):799-808. PubMed ID: 8860832
[TBL] [Abstract][Full Text] [Related]
23. The effects of pleiotrophin in proliferative vitreoretinopathy.
Ding X; Bai Y; Zhu X; Li T; Jin E; Huang L; Yu W; Zhao M
Graefes Arch Clin Exp Ophthalmol; 2017 May; 255(5):873-884. PubMed ID: 28083679
[TBL] [Abstract][Full Text] [Related]
24. Chalcomoracin prevents vitreous-induced activation of AKT and migration of retinal pigment epithelial cells.
Han H; Yang Y; Liu B; Tian J; Dong L; Qi H; Zhu W; Wang J; Lei H
J Cell Mol Med; 2021 Oct; 25(19):9102-9111. PubMed ID: 34432370
[TBL] [Abstract][Full Text] [Related]
25. siRNA targeting mammalian target of rapamycin (mTOR) attenuates experimental proliferative vitreoretinopathy.
Zhou P; Zhao MW; Li XX; Yu WZ; Bian ZM
Curr Eye Res; 2007 Nov; 32(11):973-84. PubMed ID: 18027173
[TBL] [Abstract][Full Text] [Related]
26. Idelalisib inhibits vitreous-induced Akt activation and proliferation of retinal pigment epithelial cells from epiretinal membranes.
Xin T; Han H; Wu W; Huang X; Cui J; Matsubara JA; Song J; Wang F; Colyer M; Lei H
Exp Eye Res; 2020 Jan; 190():107884. PubMed ID: 31786159
[TBL] [Abstract][Full Text] [Related]
27. Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy.
Lei H; Velez G; Hovland P; Hirose T; Kazlauskas A
Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):42-8. PubMed ID: 18172073
[TBL] [Abstract][Full Text] [Related]
28. Dabigatran inhibits intravitreal thrombin activity.
Bastiaans J; Mulder VC; van Meurs JC; Smits-Te Nijenhuis M; van Holten-Neelen C; van Hagen PM; Dik WA
Acta Ophthalmol; 2018 Aug; 96(5):452-458. PubMed ID: 29193875
[TBL] [Abstract][Full Text] [Related]
29. Effects of topoisomerase II inhibitors on retinal pigment epithelium and experimental proliferative vitreoretinopathy.
Kuo HK; Wu PC; Yang PM; Chen YH; Wu YC; Hu DN
J Ocul Pharmacol Ther; 2007 Feb; 23(1):14-20. PubMed ID: 17341145
[TBL] [Abstract][Full Text] [Related]
30. A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy.
Pennock S; Rheaume MA; Mukai S; Kazlauskas A
Am J Pathol; 2011 Dec; 179(6):2931-40. PubMed ID: 22035642
[TBL] [Abstract][Full Text] [Related]
31. Antiproliferative effect of mitomycin C on experimental proliferative vitreoretinopathy in rabbits.
Yu HG; Chung H
Korean J Ophthalmol; 1997 Dec; 11(2):98-105. PubMed ID: 9510652
[TBL] [Abstract][Full Text] [Related]
32. Antisense oligonucleotide targeting c-fos mRNA limits retinal pigment epithelial cell proliferation: a key step in the progression of proliferative vitreoretinopathy.
Zhang L; Li X; Zhao M; He P; Yu W; Dong J; Liu G; Li C; Shi X
Exp Eye Res; 2006 Dec; 83(6):1405-11. PubMed ID: 16973160
[TBL] [Abstract][Full Text] [Related]
33. Induction of proliferative vitreoretinopathy by a unique line of human retinal pigment epithelial cells.
Wong CA; Potter MJ; Cui JZ; Chang TS; Ma P; Maberley AL; Ross WH; White VA; Samad A; Jia W; Hornan D; Matsubara JA
Can J Ophthalmol; 2002 Jun; 37(4):211-20. PubMed ID: 12095094
[TBL] [Abstract][Full Text] [Related]
34. Effect of 2'-benzoyl-oxycinnamaldehyde on RPE cells in vitro and in an experimental proliferative vitreoretinopathy model.
Lee JJ; Park JK; Kim YT; Kwon BM; Kang SG; Yoo YD; Yu YS; Chung H
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):3117-24. PubMed ID: 12202537
[TBL] [Abstract][Full Text] [Related]
35. Upregulation of RAGE and its ligands in proliferative retinal disease.
Pachydaki SI; Tari SR; Lee SE; Ma W; Tseng JJ; Sosunov AA; Cataldergirmen G; Scarmeas N; Caspersen C; Chang S; Schiff WM; Schmidt AM; Barile GR
Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297
[TBL] [Abstract][Full Text] [Related]
36. Influence on collagen metabolism of vitreous from eyes with proliferative vitreoretinopathy.
González-Avila G; Lozano D; Manjarrez ME; Ruiz VM; Terán L; Vadillo-Ortega F; Selman M
Ophthalmology; 1995 Sep; 102(9):1400-5. PubMed ID: 9097780
[TBL] [Abstract][Full Text] [Related]
37. EIU in the rat promotes the potential of syngeneic retinal cells injected into the vitreous cavity to induce PVR.
Behar-Cohen FF; Thillaye-Goldenberg B; de Bizemont T; Savoldelli M; Chauvaud D; de Kozak Y
Invest Ophthalmol Vis Sci; 2000 Nov; 41(12):3915-24. PubMed ID: 11053294
[TBL] [Abstract][Full Text] [Related]
38. Effect of Methotrexate on an In Vitro Patient-Derived Model of Proliferative Vitreoretinopathy.
Amarnani D; Machuca-Parra AI; Wong LL; Marko CK; Stefater JA; Stryjewski TP; Eliott D; Arboleda-Velasquez JF; Kim LA
Invest Ophthalmol Vis Sci; 2017 Aug; 58(10):3940-3949. PubMed ID: 28777835
[TBL] [Abstract][Full Text] [Related]
39. Phosphoinositide 3-kinase δ inactivation prevents vitreous-induced activation of AKT/MDM2/p53 and migration of retinal pigment epithelial cells.
Han H; Chen N; Huang X; Liu B; Tian J; Lei H
J Biol Chem; 2019 Oct; 294(42):15408-15417. PubMed ID: 31467081
[TBL] [Abstract][Full Text] [Related]
40. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study.
Kon CH; Occleston NL; Aylward GW; Khaw PT
Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):705-12. PubMed ID: 10067974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
